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SUMMARY: In the present study, the hepato and reno-protective effect of Nigella sativa crude oil and its binary 
blend with omega-3 fatty acid-rich oils (fish and flaxseed oils) was studied in a modified hepatorenal syndrome 
model (MHRS) in rats. MHRS was induced through feeding a high fructose diet followed by an intraperitoneal 
injection of  galactosamine hydrochloride. Nigella oil and its different blends were given as a daily oral dose 
to MHRS rats. Two control groups of  MHRS and normal healthy rats were run. Different biochemical and 
nutritional parameters were assessed. The induction of  MHRS produced liver and kidney dysfunction, and 
elevated oxidative stress, an inflammatory biomarker, endothelin 1, and plasma cholesterol. Reduced plasma 
high density lipoprotein cholesterol, albumin and Ca and elevated urinary N-acetyl-β-D-Glucosaminidase and 
liver fats were noticed. The administration of Nigella crude oil that originally had 0.2% total omega-3 fatty acids 
or its blend with fish oil (17.9% omega-3) or flaxseed oil (42.1% omega-3) significantly improved all biochemical 
parameters of MHRS. There was no significant difference in the biochemical parameters among the different oil 
treated groups regardless of the omega-3 fatty acid content. This may point out to the potential profound effect 
of the volatile oil fraction of Nigella crude oil which may compensates for its low omega-3 content.
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RESUMEN: Evaluación del efecto terapéutico del aceite crudo de Nigella sativa y su mezcla con aceites ricos 
en ácidos grasos omega-3 en un modelo de síndrome hepatorenal modificado en ratas. En el presente estudio, el 
efecto hepato- y reno-protector de aceites crudos de Nigella sativa y su mezcla binaria con aceites ricos en ácidos 
grasos omega-3 (pescado y aceites de linaza) fue estudiado en un modelo modificado de síndrome hepatorenal 
(MHRS) en ratas. MHRS fue inducido a través de la alimentación de una dieta alta en fructosa seguido de 
la inyección intraperitoneal de clorhidrato de galactosamina. Diferentes aceites fueron suministrados como 
dosis oral diaria a ratas con MHRS. Se realizaron dos grupos de control de MHRS y ratas sanas normales. Se 
evaluaron diferentes parámetros bioquímicos y nutricionales. La inducción de la MHRS produce disfunción 
hepática y renal, elevado estrés oxidativo y biomarcadores inflamatorios, endotelina 1, y colesterol en plasma. 
Se observó una reducción del colesterol plasmatico de lipoproteínas de alta densidad, albúmina y Ca, elevación 
en orina de N-acetil-β-D-glucosaminidasa y de la grasa del hígado. La administración de aceite crudo de Nigella 
que tiene un 0,2% de ácidos grasos omega-3 totales o su mezcla con aceite de pescado (17,9% de omega-3) o 
aceite de linaza (42,1% de omega-3) mejoró significativamente todos los parámetros bioquímicos de MHRS. No 
hubo diferencia significativa en los parámetros bioquímicos entre los diferentes grupos tratados con los aceites 
ensayados independientemente del contenido de ácidos grasos omega-3. Con esto se puede resaltar el potencial 
efecto de la fracción volátil del aceite crudo de Nigella.
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1. INTRODUCTION
Chronic liver disease causes significant morbidity 
and mortality because of the number of complica-
tions associated with this disease. This can comprise 
hepatic encephalopathy, ascites and hepatorenal 
syndrome. Hepatorenal syndrome (HRS) is defined 
as renal failure caused by acute or chronic liver fail-
ure without any histological reasons (Bataller et al., 
1998). Two categories of HRS are described: Type 1 
(HRS) is considered to be a specific complication of 
advanced cirrhosis characterized by a rapidly pro-
gressive decrease in kidney function. It is defined as 
a 100% increase in serum creatinine to a final value 
>2.5 mg·dL−1 in less than two weeks in humans. 
Type 2 HRS occurs in the setting of refractory asci-
tes with a steady, moderate degree of  functional 
renal failure (Arroyo et al., 1996). Considering the 
management of  HRS, patients with type 1 HRS 
usually require hospitalization, whereas those with 
type 2 HRS can be treated as outpatients.
HRS is still one of  a few great secrets of  today’s 
medicine. The Pathomechanism of  this syndrome 
is still poorly understood. Therefore, the patho-
genesis of  renal function alteration associated with 
liver disease remains to be elucidated. The exact 
etiology of  HRS is unknown, although vasodilata-
tion in the splanchnic area is suggested to be the 
basic pathophysiological reason for this disease 
(Demirbas et al., 2012). Vasodilatation can develop 
as a result of  cirrhosis, portal hypertension, reflex 
systemic and splanchnic vasoconstriction. On the 
other hand, some factors were suggested to be the 
causes of  type 1 HRS including sepsis, variceal 
hemorrhage, shock, severe acute alcoholic hepa-
titis, or use of  nephrotoxics (Muñoz, 2008). The 
decrease in renal perfusion and also in the glomer-
ular filtration rate, sodium retention and deteriora-
tion of  excretion of  free water are the major renal 
problems which remain progressive according to 
the stage of  liver disease (Demirbas et al., 2012). 
Therefore, a new approach for future studies of  the 
pathology in cirrhotic patients with renal dysfunc-
tion is required. Based on the ignorance of  the exact 
mechanism of  HRS, therapy for such a syndrome 
has not yet been established, where symptomatic 
treatment is only adopted which is not a radical 
remedy. Symptomatic treatments include vasocon-
strictor therapy, in order to reverse splanchnic vaso-
dilation, together with albumin. This treatment was 
found to be effective in about 50% of  patients with 
type 1 HRS and improves survival (Fagundes and 
Ginè, 2012). These symptomatic treatments could 
reduce the risk of  developing type 2 HRS (Planas 
et al., 2006). Another treatment like renal vasodila-
tors (Snowdon et  al., 2013) is also an option for 
managing HRS. However, liver transplantation is 
considered the preferred treatment because it offers 
a cure for both liver and renal dysfunction (Wadei 
et  al., 2006). Different reviews are available dis-
closing different aspects of  this disease and more 
detailed strategies for treatment (Mohindra and 
Kumar, 2013; Davenport et al., 2012).
In Egypt and in many other developing coun-
tries there is a continuous increase in the percentage 
of patients with liver and kidney dysfunction. This 
motivated the research team of the current investiga-
tion to study the interrelation between both diseases 
represented by HRS and how to protect, overcome or 
manage through the oral administration of some nat-
ural nutraceutical oils from plant and marine sources. 
Experimental animal models could be utilized in 
order to explain the patho- physiological state, and 
the mechanisms involved in the etiology of HRS 
as well as studying new efficient therapy. So, in the 
present research galactosamine hydrochloride was 
used to induce HRS in Sprague dawley rats accord-
ing to Saracyn et al. (2012). In our previous work, 
(Al-Okbi et al., 2013) it was revealed that the crude 
oil of Nigella sativa had a promising protection from 
steatohepatitis, which is a fatty liver with inflamma-
tion in rats.
In a continuation of that trend, the  present study 
was dedicated to study the protective effect of Nigella 
sativa crude oil and its mixture with other omega-3 
fatty acid-rich oils like flaxseed or fish oil toward the 
induced modified hepatorenal syndrome (MHRS). 
MHRS was induced in rats via feeding a high fructose 
diet with a simultaneous intraperitoneal injection of 
galactosamine hydrochloride to induce steatohepati-
tis and HRS. Another objective of the current study 
was to shed light on the biochemical changes and 
biomarkers that may be related to MHRS.
2. MATERIALS AND METHODS
2.1. Materials
Mature dried seeds of black cumin (Nigella sativa L, 
family Ranunculaceae) and flaxseeds (Linum usitatis-
simum L, family Linaceae) were purchased from a 
specialized local herbal store located in Cairo, Egypt. 
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The seeds were authenticated by  Dr.  Tereez  Labib, 
a consultant of  Plant Taxonomy, Ministry of 
Agriculture, Egypt. A voucher specimen from each 
plant seed was deposited in the National Research 
Centre Herbarium, Egypt. Fish oil (a mixture of 
anchovy cod, mackerel and sardine oils) was obtained 
from an Egyptian local market in soft gelatin capsules 
under the trade name “Natrol Omega-3 Fish oil”. This 
dietary supplement is manufactured by Natrol. Inc. 
Chatsworth, CA 91311 USA. D-(+)-galactosamine 
hydrochloride was obtained from the Sigma-Aldrich 
Chemical Co. (St. Louis, MO, USA). All other chemi-
cals used in the experiment were of analytical grade 
and used as is without further purification.
2.2. Animals
Male Sprague Dawley rats weighing 120.0–165.0 g 
(mean ± SD of 141.2±12.2) were used in the present 
study. The animals were obtained from the Animal 
House of National Research Centre, Cairo, Egypt. 
The animals were kept individually in stainless 
steel metabolic cages; water and food were given 
ad-libtium.
2.3. Diets
Experimental diets were prepared as in Table 1. 
A salt mixture and vitamin mixtures were prepared 
according to previous methods (Briggs and Williams, 
1963; Morcos, 1976). Oil soluble vitamins were given 
orally in a dose of 0.1 mL/rat/week. Two types of diets 
were prepared; a balanced and a high fructose diet 
as described by Kawasaki et al. (2009) and Al-Okbi 
et al. (2013).
2.4. Extraction of Nigella and fl axseed crude oils.
Nigella sativa seeds and flaxseeds were crushed 
twice using a grinder model (MF10 microfine grinder 
drives). The crushed samples were pressed sepa-
rately with a laboratory type Carver hydraulic press 
under 10.000 lb/inch pressure at room temperature 
according to Üstun et al., 1990. The produced oil 
was filtered and kept in dark bottles under deep 
freezing conditions until use.
2.5. Blending of Nigella crude oil with fl axseed and 
fi sh oils
A certain weight of Nigella crude oil was mixed 
separately with an equal weight of either flaxseed oil 
or fish oil with continuous stirring for 5  minutes to 
ensure homogeneity. These binary oil blends (Nigella/
flaxseed and Nigella/fish at 1:1 weight  ratios) were 
left for 1 h to equilibrate at room temperature be -
fore formulation into water-based  emulsion for oral 
administration.
2.6. Formulation of Nigella crude oil and its binary 
blends in water-based emulsion for oral 
administration
Nigella crude oil and its binary blends with flax-
seed and fish oils were mixed separately with Tween 
80 as a non-ionic surfactant at 10.0% of the oils’ 
weight (e.g. 1.0 g surfactant for each 10.0 g oil or oil 
blend). The oil-surfactant mixtures were vortexed for 
1 min then left for 1h to equilibrate before a drop-wise 
addition of the oils to a calculated amount of distilled 
water. This oral administration system is called a self-
emulsifying delivery system which forms oil-in-water 
emulsion spontaneously upon titration in water.
2.7. Preparation and analysis of the fatty acid 
composition of Nigella crude oil and its 
binary blends
The oils were transformed into their correspond-
ing volatile fatty acid methyl esters via a trans- 
esterification process using 3.0% methanol/sulfuric 
acid according to A.O.A.C. (2000). Two microliters 
of the prepared fatty acid methyl esters were injected 
(at a split ratio 10:1) into a Hewlett Packard HP 6890 
gas chromatograph equipped with a flame ionization 
detector. A 30 m×0.32 mm i.d. fused silica capillary 
column coated with DB-5 was used to separate the 
different methyl esters. The oven temperature was 
programmed from 150 °C to 240 °C at a rate of 
2.5 °C·min−1 with a 30 min hold at the final temper-
ature. The injector and detector temperatures were 
230 °C and 250 °C, respectively. Helium was used as 
a carrier gas at a flow rate of  1.0 mL·min−1. Methyl 
esters were identified by comparing their reten-
tion times with the available authentic standards 
(Sigma-Aldrich, St. Louis USA). Values of area% 
were the means of two injections from two different 
extractions±SD.
A gas chromatographic-mass spectroscopic 
(GC-MS) analysis was also conducted for the full 
identification of fatty acid methyl esters. A Hewlett-
Packard 5972 GC-MS system was equipped with the 
TABLE 1. Composition of different diets (g per 100 g).
Ingredients High fructose diet (HFD) Balanced diet
Casein 17 12
Corn oil – 10
Butter fat 5.5 –
Fructose 70 –
Starch – 47
Sucrose – 23.5
Salt mix. 3.5 3.5
Vitamin mix. 1 1
Cellulose 3 3
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same column and conditions used as in GC analysis. 
The ionization voltage was 70 eV and the ion source 
temperature was 170 °C.
The full identities of the fatty acid methyl esters 
were revealed and verified by automatic matching 
of their mass fragmentation patterns (m/z) with that 
of standard components stored in the electronic 
mass spectral library (NIST: National Institute of 
Standards and Technology) that was built in to the 
GC-MS software.
2.8. Extraction and analysis of Nigella volatile oil
Nigella volatile oil was extracted from the crude oil 
via the hydro-distillation method using a Clevenger-
type apparatus (European Pharmacopoeia, 1996). 
A certain weight of the crude oil was mixed with 
distilled water at 1:5 weight/volume ratios and dis-
tilled for 3h. The weight of the obtained volatile oil 
was determined and correlated to the weight of the 
crude oil to give the yield percent. The value of the 
yield percent was an average of two extractions±SD. 
A chemical analysis of the volatile oil was conducted 
using gas chromatography in order to estimate the 
percentage of thymoquinone and p-cymene which 
are the most prominent and biologically active 
components of the volatile oil. Twenty microliters 
of the volatile oil were diluted in 1.0 mL diethyl 
ether and 2.0 μL of this mixture were injected at a 
10:1 split ratio into a Hewlett Packard HP 6890 gas 
chromatograph equipped with a flame ionization 
detector. A 30 m×0.32 mm i.d. fused silica capil-
lary column coated with DB-5 was used to separate 
the volatile oil components. The oven temperature 
was programmed from 50 °C to 220 °C at a rate of 
3 °C·min−1. The injector and detector temperatures 
were 230 °C and 250 °C, respectively. Helium was 
used as a carrier gas at a flow rate of 1.0 mL·min−1. 
Thymoquinone and p-cymene were identified by 
comparing their retention times with authentic stan-
dards (Sigma-Aldrich, St. Louis USA). Values of the 
area% of these two components were the means of 
two injections from two different extractions±SD.
2.9. Biological experiment
Thirty rats were divided into five groups, each 
comprised of six rats. The first was the normal con-
trol group where rats received a balanced diet with-
out any treatments. The rats of the second group 
were fed a high fructose diet for the induction of 
steatohepatitis (Kawasaki et al., 2009). The rats of 
groups 3, 4 and 5 were fed a high fructose diet and 
given a daily oral dose of 265mg·kg−1 rat body weight 
of N. sativa crude oil, a mixture of N. sativa crude oil 
and fish oil (1:1) and a mixture of N. sativa crude oil 
and flaxseed oil (1:1), respectively by stomach tube. 
The dose of 265 mg·kg−1 was used because N. sativa 
crude oil was reported previously to improve fatty 
liver at this dose level (Al-Okbi et al., 2013). On the 
34th day all rats except the normal healthy control 
(group: 1) were given 1.1 g·kg−1 body weight of galac-
tosamine hydrochloride via intraperitoneal injection 
as a 200 mg·mL−1 solution in saline to induce hepa-
torenal syndrome (Saracyn et al., 2012). Therefore, 
according to the last treatment, group 2 served as 
a control with both steatohepatitis and hepatorenal 
syndrome (MHRS) while groups 3-5 are test groups 
with MHRS and treated with different oils. During 
the experiment, body weight and food intake were 
recorded weekly. At the end of the study, the total 
food intake, body weight gain and food efficiency 
ratio (Body weight gain/total food intake) were cal-
culated. The whole experimental period was thirty-
five days.
Urine samples were collected twenty-four hours 
after the galactosamine hydrochloride injection for 
the determination of N-acetyl-β-D-Glucosaminidase 
(NAG) (Price and Whiting, 1992). Creatinine was 
determined in the collected 24h urine (Houot, 1985) 
for the calculation of  creatinine clearance. Blood 
samples were collected from the fasting rats 24 hours 
after the galactosamine injection. An aliquot of 
blood was used for the determination of hemoglobin 
(Hb) (VanKampen and Zijlstra, 1965). Another ali-
quot was placed in heparinized tubes and centrifuged 
for the separation of plasma. Plasma total choles-
terol (T-Ch) (Watson, 1960), high density lipoprotein 
cholesterol (HDL-Ch) (Burstein et  al., 1970), low 
density lipoprotein cholesterol (LDL-Ch) (Schriewer 
et al., 1984) and triglycerides (TG) (Megraw et al., 
1979) were determined. The HDL-Ch/T-Ch ratio 
was calculated. Plasma malondialdehyde (MDA) 
(Satoh, 1978) and total antioxidant capacity (TAC) 
(Koracevic et al., 2001) were determined as indica-
tors of  lipid peroxidation and antioxidant state, 
respectively. The plasma tumor necrosis factor-α 
(TNF-α) (an inflammatory biomarker) (Stepaniak 
et  al., 1995) was assessed. The activity of  aspar-
tate transaminase (AST) and alanine transaminase 
(ALT) (Reitman and Frankel, 1957), plasma albu-
min (Doumas et al., 1972) and total and direct biliru-
bin (Gambino, 1965) were determined as indicators 
of liver function. Plasma creatinine (Houot, 1985) 
and urea (Fawcett and Scott, 1960) were assessed 
as indicators of kidney function. Plasma endothelin 
1 (ET-1) (Zhou et al., 2002) was determined as an 
expected biomarker of the hepatorenal syndrome. 
Livers and kidneys were immediately removed and 
weighed. The livers were stored at −20 °C until anal-
ysis. Hepatic lipids were extracted and weighed as 
described by Folch et al. (1957) and Cequier-Sa´nchez 
et al. (2008). Triglyceride and cholesterol contents 
in the liver were measured according to Megraw 
et al. (1979) and Watson, (1960), respectively. The 
animal experiments were carried out according to 
the Medical Research Ethics Committee, National 
Research Centre; Cairo, Egypt.
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2.10. Statistical analysis
The results of animal experiments were expressed 
as the mean±SE and they were analyzed statistically 
using the one-way analysis of variance ANOVA fol-
lowed by Duncan’s test. In all cases p<0.05 was used 
as the criterion for statistical significance.
3. RESULTS
The fatty acid composition of Nigella crude oil 
and its binary blend with flaxseed and fish oils is 
shown in Table 2. From the table it is evident that 
Nigella crude oil is poor in omega-3 fatty acids 
(0.2%) however, it is rich in omega-6 (60.4%) and 
omega-9 (25.2%) fatty acids. Blending Nigella crude 
oil with either fish or flaxseed oil improved the total 
omega-3 content of  the mixture to reach 17.9% and 
42.1% of  the total fatty acids, respectively. This 
provides omega-6 to omega-3 ratios of  1.88 and 
0.73 for Nigella/fish and Nigella/flaxseed oil blends, 
respectively.
Table 3 shows the fatty acid composition of the 
pure individual flaxseed and fish oils that were used 
to blend with Nigella crude oil. The table confirmed 
the fact that these oils are rich sources of omega-3 
fatty acids which reached 42.7% and 57.9% for both 
fish and flaxseed oils, respectively.
The extraction of the volatile oil from Nigella crude 
oil revealed that this fraction constitutes 2.6%±0.3 of 
the crude oil’s weight. The gas chromatographic anal-
ysis revealed that thymoquinone (68.1±0.8%) and 
p-cymene (20.1±0.4%) are the major constituents of 
the volatile oil fraction.
Table 4 shows the liver and kidney functions of 
the different experimental groups. The plasma  levels 
of  the total and direct bilirubin and the plasma 
 activities of  AST and ALT were increased signifi-
cantly in the control rats with MHRS indicating 
liver dysfunction. Also plasma albumin was reduced 
significantly in the MHRS rats compared with the 
normal control rats. The plasma levels of  creatinine, 
urea and endotheline-1 (ET-1) increased signifi-
cantly in the MHRS control rats compared with the 
normal control rats, indicating kidney dysfunction. 
The oral administration of Nigella crude oil, Nigella/
fish or Nigella/flaxseed oils (which encompass the 
three test groups) showed significant improvement 
in liver and kidney functions with different degrees 
compared with the MHRS control group. On the 
other hand, plasma urea and creatinine were com-
pletely normalized on oral administration of dif-
ferent oils where they matched that of  the normal 
control rats. When comparing the test groups with 
each other, there were no significant changes in the 
parameters indicating liver and kidney functions 
TABLE 2. Fatty acids composition of Nigella, Nigella/fish and Nigella/flaxseed oils blended at 1:1 weight ratio
Fatty acid carbon No. Common name CAS Name
Average area (%)
Nigella Nigella/fish Nigella/flaxseed
C14:0 Myristic Tetradecanoic 0.1±0.07 2.0±0.4 <0.1
C16:4 – 6,9,12,15-Hexadecatetraenoic nd 0.7±0.01 nd
C16:3 (n-3) Roughanic 7,10,13-Hexadecatrienoic nd 0.6±0.01 nd
C16:1 (n-7) Palmitoleic 9-Hexadecenoic 0.1±0.07 4.2±0.2 <0.1
C16:0 Palmitic Hexadecanoic 9.5±0.5 11.5±0.5 11.4±0.07
C18:2 (n-6) Linoleic 9,12-Octadienoic 60.4±3.6 32.8±1.6 30.9±0.7
C18:3 (n3) α-linolenic 9,12,15 -Octadecatrienoic 0.2±0.07 0.2±0.05 42.1±0.6
C18:1 (n-9) Oleic 9-Octadecenoic 21.9±2.6 21.7±1.0 11.7±0.1
C18:1 (n-7) vaccenic 11-Octadecenoic 1.0±0.07 2.8±0.1 <0.1
C18:0 Stearic Octadecanoic 3.3±0.2 3.5±0.3 3.1±0.1
C20:4 (n-6) Arachidonic Eicosa-5,8,11,14-tetraenoic nd 0.9±0.01 nd
C20:5 (n-3) Timnodonic Eicosa-5,8,11,14,17-pentaenoic nd 10.2±0.6 nd
C20:4 (n-3) Eicosatetraenoic Eicosa-8,11,14,17-tetraenoic nd 0.7±0.01 nd
C20:1 (n-9) Eicosenoic 11-Eicosenoic 3.3±0.2 3.1±0.04 1.2±0.1
C22:6 (n-3) Cervonic acid Docosa-4,7,10,13,16,19-hexaenoic nd 5.2±0.5 nd
C22:5 (n-3) Clupanodonic Docosa-7,10,13,16,19-pentaenoic nd 1.0±0.2 nd
Total n-9 25.2% 24.8% 12.9%
Total n-6 60.4% 33.7% 30.9%
Total n-3 0.2% 17.9% 42.1%
Ratio n-6/n-3 302 1.88 0.73
nd: not detected.
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reflecting an equal effect of  the different oils in im -
proving such parameters.
Table 5 shows the plasma and liver lipid profile 
of  the different experimental groups. MHRS con-
trol rats exhibited a significant increase in plasma 
total cholesterol, triglycerides, LDL-Ch and the 
ratio of  T-Ch/HDL-Ch compared with the nor-
mal control rats. In addition, significant increases 
were observed in total fat, T-Ch and TG in the liver 
tissue of  the MHRS control rats compared to the 
normal control group.
The rats of the test groups showed a significant 
improvement in plasma lipid profile, T-Ch/HDL-Ch 
and the contents of total liver fat, T-Ch and TG with 
different degrees.
Table 6 shows the blood hemoglobin, total an -
tioxidant capacity, malondialdehyde and tumor 
necrosis factor-alpha of the different  experimental 
groups. Blood hemoglobin and total plasma antioxi-
dants were reduced significantly in the MHRS con-
trol rats compared with the normal control group. 
The oral administrations of  different oils elevated 
TABLE 3. Fatty acid composition of the pure fish and flaxseed oils.
Fatty acid carbon No. Common name CAS Name
Average area (%)
Fish oil Flaxseed oil
C14:0 Myristic Tetradecanoic 4.82±0.2 nd
C16:4 – 6,9,12,15-Hexadecatetraenoic 1.72±0.01 nd
C16:3 (n-3) Roughanic 7,10,13-Hexadecatrienoic 1.28±0.01 nd
C16:1 (n-7) Palmitoleic 9-Hexadecenoic 8.45±0.1 nd
C16:0 Palmitic Hexadecanoic 13.44±0.3 7.0±0.1
C18:4 (n3) Stearidonic 6,9,12,15-Octadecatetraenoic 3.20±0.1 nd
C18:2 (n-6) Linoleic 9,12-Octadienoic 1.57±0.01 12.4±0.2
C18:1 (n-9) Oleic 9-Octadecenoic 10.85±0.2 16.8±1.5
C18:3 (n-3) α -linolenic 9,12,15 -Octadecatrienoic 0.44±0.01 57.9±2.4
C18:1 (n-7) vaccenic 11-Octadecenoic 3.90±0.1 nd
C18:0 Stearic Octadecanoic 3.64±0.1 4.5±0.2
C20:4 (n-6) Arachidonic Eicosa-5,8,11,14-tetraenoic 1.17±0.01 nd
C20:5 (n-3) Timnodonic Eicosa-5,8,11,14,17-pentaenoic 20.15±1.8 nd
C20:4 (n-3) Eicosatetraenoic Eicosa-8,11,14,17-tetraenoic 1.37±0.01 nd
C20:1 (n-9) Eicosenoic 11-Eicosenoic 1.73±1.03 nd
C22:6 (n-3) Cervonic acid Docosa-4,7,10,13,16,19-hexaenoic 13.77±0.4 nd
C22:5 (n-3) Clupanodonic Docosa-7,10,13,16,19-pentaenoic 2.51±0.1 nd
Total n-9 12.5% 16.8%
Total n-6 2.7% 12.4%
Total n-3 42.7% 57.9%
nd: not detected.
TABLE 4. Liver and kidney functions of different experimental groups*
Plasma Parameters Normal control
MHRS 
control Nigella oil
Nigella oil & 
Fish oil (1:1)
Nigella oil & 
Flaxseed oil (1:1)
Creatinine (mg·dL−1) 0.686a±0.04 1.04b±0.1 0.761a±0.03 0.744a±0.04 0.806a±0.03
Urea (mg·dL−1) 30.3a±1.1 44.3b±2.8 30.3a±0.5 30.2a±0.2 30.1a±0.7
Albumin (g·dL−1) 4.2a±0.2 2.65b±0.1 3.1c±0.1 3.2c±0.1 3.2c±0.1
ALT (U/l) 55.8a±1.2 86.2b±1.9 76.7c±2.2 74c±1.8 72.7c±1.4
AST (U/l) 40.8a±0.8 80.5b±1.4 70.2c±2.6 67.5c±2.1 66.7c±1.7
T. Bilirubin (mg·dL−1) 0.356a±0.01 0.497b±0.01 0.411c±0.01 0.395c±0.01 0.383c±0.02
D. Bilirubin (mg·dL−1) 0.157a±0.004 0.242b±0.01 0.18c±0.01 0.167c±0.01 0.162c±0.01
ET-1 (ng·mL−1) 22.0a±1.3 39.7b±2.8 27.2c±1.7 26.3c±2.4 27.7c±1.1
*Mean±S.E.
In the same row, values having the same letter are insignificantly different and values having different letters 
are significantly different at the level p<0.05.
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blood hemoglobin and plasma TAC levels to differ-
ent degrees. The plasma levels of MDA and TNF-α 
increased significantly in the MHRS control rats com-
pared with the normal control group. The MHRS 
rats administered different oils showed a significant 
reduction in MDA levels and TNF-α. Blood hemo-
globin, plasma total antioxidant capacity and plasma 
malondialdehyde levels of the test groups were still 
not matching that of the normal control group.
Table 7 shows that creatinine clearance was reduced 
significantly in the MHRS control group compared 
to normal control rats. The administration of differ-
ent oils showed a significant increase in creatinine 
clearance compared with the MHRS control group.
The urine level of NAG (Table 5) was elevated sig-
nificantly in the MHRS group compared to the nor-
mal control rats. The administration of different oils 
showed a significant reduction in NAG compared 
with the MHRS control group.
Table 8 shows the non-significant changes when 
all nutritional parameters, liver weight/body weight % 
and kidney weight/body weight % of  the MHRS 
control rats were compared with the normal control 
rats. The oral administration of different oils showed 
non-significant changes in all the aforementioned 
parameters except for the rats given the oral admin-
istration of Nigella sativa crude oil which showed 
a significant reduction in final body weight, body 
weight gain and food efficiency ratio in comparison 
to all the conducted groups.
TABLE 5. Plasma and liver lipid profile of different experimental groups*
Parameters Normal control MHRS control Nigella oil
Nigella oil & 
fish oil
Nigella oil & 
flaxseed oil
Plasma
T-Cholesterol (mg·dL−1) 82.8a±3.0 112.1b±2.8 92.4c±2.4 91.5c±1.8 92.5c±1.1 
Triglycerides (mg·dL−1) 83.1a±2.7 162.4b±2.4 130.3c±4.0 128.7c±2.5 129.5c±1.6
HDL-Ch (mg·dL−1) 31.8a±1.2 21.8b±0.6 28.7c±0.7 30.5c±1.1 30.7c±0.9
LDL-Ch (mg·dL−1) 22.3a±0.4 81.5b±2.1 55.5c±2.9 52.3c±2.4 53.3c±2.3
T-Ch/ HDL-Ch 2.6a±0.1 5.2b±0.2 3.2c±0.1 3.0c±0.1 3.0c±0.1
Tissue
Liver total fat (mg·g−1 tissue) 23.2a±0.3 44.2b±1.2 32c±0.7 30.5c±0.7 30.8c±0.4
Liver T-Cholesterol (mg/g tissue) 2.2a±0.2 7.1b±0.2 5.2c±0.1 4.9c±0.05 5.1c±0.1
Liver Triglycerides (mg·g−1 tissue) 5.3a±0.1 13.95b±0.5 8.4c±0.2 8c±0.2 8.2c±0.2
*Mean±S.E.
In the same row, values having the same letter are insignificantly different and values having different letters are 
significantly different at level p<0.05.
TABLE 6. Hemoglobin, total antioxidant capacity, malondialdehyde 
and tumor necrosis factor-alpha of different experimental groups*
Parameters Normal control MHRS control Nigella oil
Nigella oil & 
Fish oil
Nigella oil & 
Flaxseed oil
Hb (g·dL−1) 13.3a±0.543 9.9b±0.467 11.8c±0.718 12.1c±0.774 12.6c±0.581
TAC (mm·L−1) 1.57a±0.038 0.872b±0.036 1.21c±0.058 1.28c±0.070 1.3c±0.058
MDA (nmol·mL−1) 5.5a±0.217 23.1b±0.634 15.7c±0.685 14.2c±0.958 14.8c±0.777
TNF-α (pg·mL−1) 19.7a±0.604 31.7b±0.735 15.1c±0.506 14.1c±0.774 14.7c±0.882
*Mean±S.E.
In the same row, values having the same letter are insignificantly different and values having different letters are 
significantly different at the level p<0.05.
TABLE 7. Creatinine clearance and NAG 
of different experimental groups*
Groups
Creatinine 
clearance (ml/min)
NAG 
(IU/l)
Normal control 0.945ª±0.05 38.1ª±0.66
MHRS 0.501b±0.07 46.1b±1.8
Nigella sativa oil 0.636c±0.05 36.9c±2.5
Nigella sativa oil & fish oil 0.686c±0.06 35.2c±1.7
Nigella sativa oil & Flaxseed oil 0.705c±0.04 37.0c±1.3
*Mean±SE.
In the same column, values having the same letter are 
insignificantly different and values having different letters are 
significantly different at level p<0.05.
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4. DISCUSSION
In the present study it was decided to induce ste-
atohepatitis before the induction of  HRS with the 
aim of enhancing the induction of  HRS on intra-
peritoneal injection with galactosamine hydrochlo-
ride. MHRS in the current study referred to the 
blend of  steatohepatitis and HRS. It was also the 
interest of  the authors in the present study to assess 
the biochemical and nutritional changes that occur 
during MHRS in a trial to study the mechanism 
of action and patho-physiology of  the hepatorenal 
syndrome.
From the obtained results, this model was found to 
be satisfactory for studying the therapeutic potential 
of the investigated oils against HRS, because both 
renal and hepatic dysfunction occurred on intraperi-
toneal injection of galactosamine hydrochloride.
The increased plasma creatinine and reduced 
creatinine clearance in MHRS in the present study 
reflected that glomerular function, proximal tubules 
and glomerular filtration rate are affected in HRS 
as reported previously (Van Lente and Sult, 1989; 
Skálová, 2005). Renal dysfunction in patients with 
cirrhosis with superimposed inflammation was 
reported previously to be associated with signifi-
cant tubular injury (Shah et al., 2013). This model 
also showed elevated oxidative stress in the pres-
ent study, represented by the increased MDA and 
the reduced total antioxidant which might be a 
biomarker of tissue destruction and inflammation 
in both kidney and liver. In the MHRS model, an 
elevated inflammatory biomarker (tumor necrosis 
factor-alpha) was also noticed in the current results. 
The inhibition of oxidative stress and simultaneous 
inflammatory biomarker, were reported to prevent 
the development of renal failure in an animal model 
of HRS (Saracyn, et al., 2008). Therefore, a natu-
ral anti-inflammatory and antioxidant might have 
therapeutic potential towards HRS.
ET-1 showed a significant elevation in the MHRS 
model in the present study, which supports the previous 
proposal of being a biomarker of HRS (Anand et al., 
2002) due to the increased endothelin (A) of the renal 
cortex which is important in the pathogenesis of renal 
failure that occurs in patients with acute liver failure 
or HRS. Urinary NAG was significantly elevated 
in the MHRS model in the present study reflecting 
tubular dysfunction and kidney parenchymal dam-
age as reported by Skálová (2005). In agreement with 
this result, high urinary NAG was reported in infants 
with liver cirrhosis (Aydogdu et al., 2004) pointing to 
an occurrence of renal dysfunction and HRS. The 
plasma albumin level was reduced significantly in 
MHRS rats in the present study which confirms the 
work of García-Martínez et  al. (2013), who showed 
that not only albumin concentration but also albumin 
function is reduced in liver failure.
Hemoglobin reduction was noticed in MHRS in 
rats, pointing to some sorts of anemia. Anemia is 
prevalent in chronic kidney disease which could be 
due to erythropoietin deficiency, inhibition of eryth-
ropoiesis by uremic solutes, and reduction in red 
blood cell life span. Other possible causes include 
iron, B12 or folic acid deficiency or blood loss. 
Dysfunction of the endogenous erythropoietin is 
usually clinically evident once the glomerular filtra-
tion rate falls below 20.0–25.0 mL·min−1 in humans 
(Ansari et al., 2014).
Rats with MHRS showed a significant elevation 
in all liver fat with dyslipidemia which may be due 
to feeding high fructose as described by Kawasaki 
et al. (2009) and Al-Okbi et al. (2013). Nigella sativa 
oil showed previously to produce a hepatoprotec-
tive effect in rats (Al-Suhaimi, 2012) which was con-
firmed by the work of Al-Okbi et  al. (2013), who 
reported its protective effect against steatohepatitis. 
This effect was ascribed to the volatile oil fraction, 
particularly thymoquinone and p-cymene and to a 
lesser extent to the fatty acid profile of Nigella crude 
oil. So, it was important to extend the study on the 
protective effect of Nigella sativa crude oil in rats 
in which MHRS was induced. The quantity and 
quality of the volatile oil fraction of Nigella sativa 
TABLE 8. Nutritional parameters of different experimental groups*
Parameters Normal control MHRS control Nigella oil
Nigella oil 
& fish oil
Nigella oil & 
flaxseed oil
Initial BW(g) 141.3a±6.2 141a±6.8 141.2a±6.69 141.3a±2.4 141a±3.2
Final BW (g) 225a±6.8 228.2a±4.7 207.3b±7.1 227.8a±7.6 228.2a±4.2
Body weight gain (g) 83.7 a±2.01 87.2a±3.7 66.2b±2.8 86.5a±5.8 87.2a±5.5
Total Food intake (g) 512.8 a±8.1 518.8a±4.2 508.5a±2.3 510.3a±6.9 514.8a±7.8
Food efficiency ratio 0.163a±0.01 0.168a±0.07 0.130b±0.05 0.169a±0.09 0.169a±0.01
Liver weight/body weight % 2.6a±0.1 2.7a±0.2 2.9a±0.3 2.8a±0.2 2.8a±0.2
Kidney weight/body weight % 0.699a±0.02 0.74a±0.01 0.896a±0.05 0.805a±0.05 0.843a±0.04
*Mean±S.E.
In the same row, values having the same letter are insignificantly different and values having different letters are 
significantly different at level p<0.05.
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crude oil used in the present study differs from that 
used to evaluate the protective effect against steato-
hepatitis in our previous work (Al-Okbi et al. 2013). 
The crude oil in the current study contains a higher 
volatile oil fraction (2.6 wt%) and different contents 
of the volatile constituents thymoquinone (68.1%, 
GC area) and p-cymene (20.1%, GC area) than in 
the previous work in which these parameters were 
0.1 wt%, 39.1%, and 40.2%, respectively.
Concerning the fatty acid composition of Nigella 
crude oil, the current study showed that the oil is 
rich in omega-6 (60.4%) and omega-9 (25.2%) but 
scarce in omega 3- fatty acids (0.2%). Therefore, 
due to the role of  omega-3 fatty acids as hepato- 
protective and anti-inflamatory agents (Raptis et al., 
2014; Al-Okbi and Mohamed, 2012), it was decided 
in the present study to blend Nigella crude oil with 
other omega-3 fatty acid rich oils from marine as 
well as plant origins such as fish and flaxseed oils, 
respectively.
In the current study, treatment with Nigella crude 
oil or its binary blend with either fish or flaxseed oils 
produced a significant improvement in all biochemi-
cal parameters. This improvement only reaches the 
normal levels in the case of plasma creatinine and 
urea and even showed a more significant improve-
ment than normal concerning plasma TNF-α. All 
other biochemical parameters, although significantly 
improved, did not reach the level of the normal group. 
This means that the different treatments did not pro-
vide complete protection, but reduced the progres-
sion of HRS. There were no significant changes in 
the biochemical parameters among the different test 
groups (kept on different oil treatments). This result 
showed that blending half the dose of Nigella crude 
oil with either flaxseed oil or fish oil produced no 
further improvement in the biochemical parameters 
compared with Nigella crude oil alone. This means 
that increasing omega-3 fatty acids at the expense of 
crude oil constituents including fatty acids and vola-
tile oils did not add to the hepato-protective effect of 
Nigella crude oil. It is well documented that decreas-
ing the ratio of n-6/n-3 fatty acids renders the oil anti-
inflammatory and beneficial health effect. Although 
the present oil blends showed lower n-6/n-3 fatty acids 
than Nigella crude oil, they did not afford extra ben-
eficial effects towards MHRS. This may be explained 
on the basis of the presence of volatile oils in Nigella 
crude oil (present at 2.6%) that possess antioxidant 
and anti-inflammatory activity. Some other constitu-
ents not determined in the present study could also 
be responsible for the biological activity of Nigella 
sativa crude oil; these are phytosterols and alpha and 
gamma- tocopherols (Cheikh-Rouhou et  al., 2008; 
Ramadan et  al., 2012) that possess antioxidant and 
anti-inflammatory effects. Although fish oil and flax-
seed oil contain high percentages of omega-3 fatty 
acids, they lack the presence of antioxidants  compared 
to Nigella crude oil.
Hyperbilirubinemia as shown in MHRS models 
in the present study might be detrimental to liver 
and renal functions. The systemic reduction in bili-
rubin concentration by the different oil treatments 
might contribute to the normalization of the urinary 
levels of prostaglandins and thromboxane B2, to 
decrease in serum bile acid levels, and to the improve-
ment of the hepatic energy charge that may reflect 
improvement in both liver and kidney dysfunctions 
as reported by Kamisako et al. (1998).
It could be noticed from the present study that 
although polyunsaturated omega-3 fatty acids were 
higher in rats given the mixture of Nigella crude oil 
with either fish oil or flaxseed oil, MDA was not 
elevated and total antioxidant was not reduced, but 
improved. This could be due to the presence of antiox-
idant constituents supplemented from N. sativa crude 
oil. The results of studies examining the effects of 
increased proportions of polyunsaturated fatty acids 
in the diet on indexes of lipid peroxidation in vivo 
are contradictory (Wander et al., 1996; Harats et al., 
1991; Meydani et al., 1991). With fish-oil supplemen-
tation, there was no evidence of increased lipid per-
oxidation when assessed by plasma F2-isoprostanes 
and MDA (Higdon et al., 2000), which agreed with 
the present study.
Diets relatively high in unsaturated fat have 
favorable effects on lipoprotein-cholesterol profiles 
(Mensink and Katan, 1992; Mattson and Grundy, 
1985) which agreed with the present results. It was 
also shown previously that chronic supplementa-
tion of fish oil demonstrated a reno-protective effect 
(Fernandez et al., 2004) which confirms the present 
results.
Flaxseeds is a leading source of  α –linolenic 
acid (ALA) which account for 57.9% of total fatty 
acids. In the present study, this amount was higher 
than that reported previously (52%) by Oomah and 
Mazza (1995). Mohamed et al. (2005) showed that 
flaxseed produced a reduction in plasma T-ch and 
LDL-ch in hyper-cholesterolemic rats. The same 
effect was reported for the consumption of  flax-
seed in humans (Clark et al., 1995; Jenkins et al., 
1999). ALA, which is an omega-3-fatty acid, has 
been reported to be useful in the prevention and 
treatment of coronary artery disease and hyperten-
sion (Simopoulos, 1999). This is because ALA is 
the precursor for the synthesis of eicosapentaenoic 
(EPA) and docosahexaenoic acids (DHA) which are 
associated with the control of cardiovascular dis-
eases (Bibus et al., 1998). ALA also reduces serum 
triglycerides and the development of thrombosis 
and arteriosclerosis (Pszczola, 1998). Also, flaxseed 
was shown to have an impact on the treatment of 
lupus nephritis (Clark et al., 1995) in humans and 
improvement of renal dysfunction during cisplatin 
treatment in rats (Al-Okbi et al., 2014), pointing 
to its reno-protective effect. Flaxseed oil attenuated 
the decline in renal function and reduced glomerular 
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injury (Caligiuri et al., 2013). It has also been shown 
that treatment with flaxseed oil caused a significant 
improvement in the histopathological picture of the 
kidney as well as the kidney function and antioxi-
dant status, against lead acetate-induced renal tox-
icity (Abdel-Moneima et al., 2011). It was reported 
that rats fed a flaxseed-supplemented diet had sig-
nificantly lower blood pressure and a significantly 
improved lipid profile, liver and kidney functions in 
the hypertensive condition. These effects are likely 
to be mediated by the ALA and linoleic acid con-
tents of flaxseed oil (Al-Bishri, 2013).
The treatment of  MHRS rats with mixtures of 
oils containing omega-3 fatty acids produced an 
improvement in renal function in the present study. 
Over the past 25 years, several studies have sug-
gested the efficacy and potential clinical utility of 
dietary supplementation with omega-3 fatty acids in 
human renal diseases (Donadio, 2001; De Caterina 
et al., 1994; Baggio et al., 2002; Azar et al., 1989).
It is accepted that the effect of  omega-3 fatty 
acids on kidney diseases related to the activities 
of  metabolites derived from EPA opposed those 
derived from arachidonic acid (AA). Alterations in 
eicosanoid synthesis and metabolism are produced 
when concentrations of  EPA and DHA increase in 
relation to AA. For example, the renal production 
of  thromboxane A2 is elevated in several renal dis-
eases and treatment with n-3 fatty acids reduced it 
(Fernandez et al., 2004).
The non significant changes in different nutri-
tional parameters in the present study are similar to 
the results reported by Kawasaki et al. (2009) and 
Al-Okbi et al. (2013) when rats fed similar high fruc-
tose diets without a glucosamine injection were com-
pared with balanced diets. The significant reduction 
in final body weight, body weight gain and food effi-
ciency ratio on administration of Nigella crude oil 
agreed with previous results (Al-Okbi et  al., 1997; 
Houcher et al., 2007).
5. CONCLUSION
MHRS induced in rats through feeding a high 
fructose diet followed by an intraperitoneal injec-
tion of galactosamine hydrochloride produced liver 
and kidney dysfunction. The same model showed 
reduced hemoglobin, elevated oxidative stress, in -
creased inflammatory biomarker, elevated ET-1, ele-
vated plasma cholesterol, reduced plasma HDL-Ch, 
reduced plasma albumin, reduced plasma Ca and 
elevated urinary NAG and liver fats. These changes 
confirm the induction of HRS. The administration of 
Nigella crude oil or its blend with fish or flaxseed oils 
significantly improved all biochemical parameters of 
MHRS but without complete protection. Changing 
the fatty acid profile of Nigella crude oil by blending 
with those omega-3 fatty acid-rich oils did not make 
any difference in the therapeutic efficiency of Nigella 
crude oil alone. That can reflect the  superiority of this 
oil and potentially its volatile oil fraction as hepato-
protective agents.
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